Easy to use. Detailed screening report.
The EyeScreen Human+AI Diagnostic Service provides an actionable, easy to read, ICD 10 compliant report, allowing seamless documentation of the patient visit. With EyeScreen you can offer DR screening in your clinic to improve patient outcomes and reduce incidence of DR releated vision loss.
Human Grading and Artificial Intelligence in Harmony
EyeScreen Service uses both a validated AI system and specialist human graders to assess retinal images. After these images are independently assessed by both the AI disease detection software and human graders separately, an ICD10 compliant report is sent to the physician. In the event that the AI and human graders disagree, the images are adjudicated by a highly experienced human expert.
High Sensitivity & Specificity ⇒ Better Safety and Better Outcomes
Combining the high accuracy of AI disease detection with the accepted practice of human grading, EyeScreen is designed to improve the overall safety of the system in contrast to other teleretinal screening services that only use human grading.
High Sensitivity = Safety | High Specificity = Effectiveness
Can help ensure patients with silently progressing DR are identified in time for referral to an eyecare specialist while reducing unnecessary referrals. Can help focus on those patients with greatest need for care.
Actionable reporting
EyeScreen provides an actionable, easy to read, ICD 10 compliant report, allowing seamless documentation of
the patient visit. The report provides eye level and patient level diabetic retinopathy outputs and also indicate severity of DR and presence or absence of macular edema.
Technology behind EyeScreen™
* Products were supported by Award numbers R44EB013585, R42TR000377, R44TR000377, R43EY024848, R43EY025984, SB1EY027241, and R43EY028081 from the National Institutes of Health (NIH). The content is solely the responsibility of Eyenuk, Inc. and does not necessarily represent the official views of NIH.
** The devices are covered by one or more of the following US patents and their foreign counterparts: 8879813, 8885901, 9002085, and 9008391. Additional patents are pending.
EyeArt has US FDA clearance and Health Canada license for the autonomous detection of DR. It has CE marking as a class IIb medical device in the European Union, under EU MDR for the autonomous detection of DR, AMD, and glaucomatous optic nerve damage.
EyeMark™, EyeReadUWF™ have not yet been cleared for sales in any region.